http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pham Thi Minh Phuc 강원대학교 대학원 2024 국내석사
Background: Non-alcoholic fatty liver disease (NAFLD), which is a progressive disease caused by a build-up of fat in the liver, onsets with simple steatosis and potentially advances to non-alcoholic steatohepatitis (NASH) in the presence of inflammation and fibrosis, severely leading to cirrhosis or hepatocellular carcinoma. There is increasing cumulative evidence indicating that sodium-glucose cotransport 2 (SGLT2) inhibitor agents efficaciously alleviate NASH in a mouse model, but there is lack of research mentioning the effect of enavogliflozin on liver disease. Consequently, in this present study, I investigated the impact of this sodium-glucose cotransport 2 inhibitor on high-fat high-cholesterol (HFHC)-diet induced NASH mice. Methods: Male C57BL/6 mice were fed a normal chow diet (CD), HFHC diet, or HFHC diet with enavogliflozin for 12 weeks. Enavogliflozin was administered at a dose of 1.28 mg/kg/day in these experiments. In vitro, LX-2 cells and HepG2 cells were treated with enavogliflozin and different pathological factors. Results: HFHC induced excessive hepatic lipid accumulation, immune cell infiltration, and severe fibrosis. Enavogliflozin administration not only ameliorated hepatic steatosis and fibrotic condition but also suppressed the production of inflammatory cytokines (IL-6, IL-1β). Similar outcomes were observed in in vitro experiments, where enavogliflozin not only hindered the activation of hepatic stellate cells but also mitigated lipid accumulation in hepatocytes. The potential pathway through which enavogliflozin attenuated liver fibrosis development may be associated with the TGF- β1/Smad signaling pathway. Conclusion: My results suggest that enavogliflozin shows efficacy in a mouse model of NASH by attenuating hepatic steatosis, suppressing inflammation, and improving liver fibrosis. Keywords: Enavogliflozin; HFHC diet; Hepatic Stellate Cells; HepG2 cells; Liver Fibrosis; NAFLD; NASH